Aerie Pharmaceuticals Logo

Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022

04/20/2022

Data adds to real-world use and clinical research on netarsudil (Rhopressa®)

DURHAM, N.C.--(BUSINESS WIRE)--Apr. 20, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that three abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., on April 22 through 26, 2022.

Gary Sternberg, M.D., Chief Medical Officer at Aerie commented, "Aerie is pleased to have multiple scientific presentations on our innovative product and product candidates being presented at the ASCRS meeting in Washington, DC. Dr. Richard Lindstrom will present on his study group's experience with the use of netarsudil in patients with Fuchs Corneal Dystrophy. In addition, there will be a presentation highlighting the results from our robust Phase 2b study of AR-15512 in dry eye disease given by Dr. David Wirta. An independent research poster will also be available on-demand on the use of netarsudil after glaucoma surgery. These presentations will add to the real-world use and clinical research on netarsudil in different patient populations.”

Aerie Research Presentations:

Title: Randomized, Open-Label, Parallel-Group Study of Two Dosing Regimens of Netarsudil in Patients with Fuchs Corneal Dystrophy

Presenting Author:

Richard Lindstrom, MD, ABO

Date/Time:

Saturday, April 23, 2022 4:26 – 4:31 p.m. ET

Location:

WEWCC – Level I, 144B

 

 

Title: Safety and Efficacy of a TRPM8 Agonist for the Treatment of Dry Eye Disease

Presenting Author:

David L. Wirta, MD

Date/Time:

Sunday, April 24, 2022, 8:05 – 8:10 a.m. ET

Location:

WEWCC – Level I, 144A

 

 

Independent Research Presentation:

Title: Netarsudil Efficacy in Open Angle Glaucoma Following Either Trabeculectomy or Tube Shunt Surgery

Presenting Author:

Brandon Wummer, BSc

Date/Time:

On-demand E-poster session, 6:30 – 6:35 a.m. ET (on-demand E-poster)

Location:

WEWCC

About Aerie Pharmaceuticals, Inc.

Aerie is a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Aerie’s first novel product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second novel product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil (0.02%) and latanoprost ophthalmic solution (0.005%)), was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. More information on Aerie Pharmaceuticals is available at www.aeriepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “exploring,” “pursuing” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements in this release include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our commercial franchise and our pipeline, any guidance or timelines and our ongoing and anticipated preclinical studies and clinical trials. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, industry change and other factors beyond our control, and depend on regulatory approvals and economic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading “Risk Factors” in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Media:
Carolyn McAuliffe
cmcauliffe@aeriepharma.com
(949) 526-8733

Investors:
LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc.
Hans Vitzthum
hans@lifesciadvisors.com
(617) 430-7578

Source: Aerie Pharmaceuticals, Inc.

TOP